Literature DB >> 33813261

One Quarter of Medicare Hospitalizations in Patients with Systemic Lupus Erythematosus Readmitted within Thirty Days.

Christie M Bartels1, Ann Chodara2, Yi Chen3, Xing Wang3, W Ryan Powell4, Fangfang Shi4, Maria Schletzbaum5, Ann M Sheehy6, Farah A Kaiksow6, Andrea L Gilmore-Bykovskyi7, Shivani Garg8, Menggang Yu3, Amy J Kind9.   

Abstract

OBJECTIVE: Thirty-day hospital readmissions in systemic lupus erythematosus (SLE) approach proportions in Medicare-reported conditions including heart failure (HF). We compared adjusted 30-day readmission and mortality among SLE, HF, and general Medicare to assess predictors informing readmission prevention.
METHODS: This database study used a 20% sample of all US Medicare 2014 adult hospitalizations to compare risk of 30-day readmission and mortality among admissions with SLE, HF, and neither per discharge diagnoses (if both SLE and HF, classified as SLE). Inclusion required live discharge and ≥12 months of Medicare A/B before admission to assess baseline covariates including patient, geographic, and hospital factors. Analysis used observed and predicted probabilities, and multivariable GEE models clustered by patient to report adjusted risk ratios (ARRs) of 30-day readmission and mortality.
RESULTS: SLE admissions (n=10,868) were younger, predominantly female, more likely to be Black, disabled, and have Medicaid or end-stage renal disease (ESRD). Observed 30-day readmissions of 24% were identical for SLE and HF (p = 0.6), and higher than other Medicare (16%, p < 0.001). Both SLE and HF had elevated readmission risk (ARR 1.08, (95% CI (1.04, 1.13)); 1.11, (1.09, 1.13)). SLE readmissions were higher for Black (30%) versus White (21%) populations, and highest in ages 18-33 (39%) and ESRD (37%). Admissions of Black patients with SLE from least disadvantaged neighborhoods had highest 30-day mortality (9% versus 3% White).
CONCLUSION: Thirty-day SLE readmissions rivaled HF at 24%. Readmission prevention programs should engage young, ESRD patients with SLE and examine potential causal gaps in SLE care and transitions.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Comorbidity; Disparities; Medicare; Quality of Care; Systemic lupus erythematosus (SLE)

Mesh:

Year:  2021        PMID: 33813261      PMCID: PMC8106659          DOI: 10.1016/j.semarthrit.2021.02.006

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.431


  25 in total

1.  Causes and Predictors of Early Hospital Readmission in Systemic Lupus Erythematosus.

Authors:  Angelica Nangit; Connie Lin; Mariko L Ishimori; Brennan M R Spiegel; Michael H Weisman
Journal:  J Rheumatol       Date:  2018-04-15       Impact factor: 4.666

2.  Systematic Review and Meta-analysis of Pharmacist-Led Transitions of Care Services on the 30-Day All-Cause Readmission Rate of Patients with Congestive Heart Failure.

Authors:  Connor McKay; Chanhyun Park; Jongwha Chang; Marcia Brackbill; Jae-Young Choi; Jung Heon Lee; Sean Hyungwoo Kim
Journal:  Clin Drug Investig       Date:  2019-08       Impact factor: 2.859

3.  How Leading Hospitals Operationalize Evidence-Based Readmission Reduction Strategies: A Mixed-Methods Comparative Study Using Systematic Review and Survey Design.

Authors:  Bita A Kash; Juha Baek; Ohbet Cheon; Joanna-Grace Mayo Manzano; Stephen L Jones; Jaya Paranilam; Robert A Phillips
Journal:  Am J Med Qual       Date:  2019-02-04       Impact factor: 1.852

4.  Individual- and Area-Level SES in Diabetes Risk Prediction: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Paul J Christine; Rebekah Young; Sara D Adar; Alain G Bertoni; Michele Heisler; Mercedes R Carnethon; Rodney A Hayward; Ana V Diez Roux
Journal:  Am J Prev Med       Date:  2017-08       Impact factor: 5.043

Review 5.  The care span: The importance of transitional care in achieving health reform.

Authors:  Mary D Naylor; Linda H Aiken; Ellen T Kurtzman; Danielle M Olds; Karen B Hirschman
Journal:  Health Aff (Millwood)       Date:  2011-04       Impact factor: 6.301

6.  Identification of patients with systemic lupus erythematosus in administrative healthcare databases.

Authors:  J G Hanly; K Thompson; C Skedgel
Journal:  Lupus       Date:  2014-07-23       Impact factor: 2.911

7.  Harnessing Protocolized Adaptation in Dissemination: Successful Implementation and Sustainment of the Veterans Affairs Coordinated-Transitional Care Program in a Non-Veterans Affairs Hospital.

Authors:  Amy J H Kind; Maria Brenny-Fitzpatrick; Kris Leahy-Gross; Jacquelyn Mirr; Elizabeth Chapman; Brooke Frey; Beth Houlahan
Journal:  J Am Geriatr Soc       Date:  2016-01-25       Impact factor: 5.562

8.  Risk adjustment of Medicare capitation payments using the CMS-HCC model.

Authors:  Gregory C Pope; John Kautter; Randall P Ellis; Arlene S Ash; John Z Ayanian; Lisa I Lezzoni; Melvin J Ingber; Jesse M Levy; John Robst
Journal:  Health Care Financ Rev       Date:  2004

9.  Neighborhood disadvantage and chronic disease management.

Authors:  Shayla N M Durfey; Amy J H Kind; William R Buckingham; Eva H DuGoff; Amal N Trivedi
Journal:  Health Serv Res       Date:  2018-11-23       Impact factor: 3.402

10.  Investigating lupus retention in care to inform interventions for disparities reduction: an observational cohort study.

Authors:  Christie M Bartels; Ann Rosenthal; Xing Wang; Umber Ahmad; Ian Chang; Nnenna Ezeh; Shivani Garg; Maria Schletzbaum; Amy Kind
Journal:  Arthritis Res Ther       Date:  2020-02-22       Impact factor: 5.156

View more
  2 in total

1.  Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study.

Authors:  Rayan Najjar; Swetha A Alexander; Grant C Hughes; Jinoos Yazdany; Namrata Singh
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-04-19       Impact factor: 5.178

2.  Prevalence of hospital readmissions and related factors in patients with autoimmune diseases.

Authors:  Tatiana Morales-Tisnés; Lina Quintero-Ortiz; Elías Quintero-Muñoz; Fabio Sierra-Matamoros; Julián Arias-Aponte; Adriana Rojas-Villarraga
Journal:  J Transl Autoimmun       Date:  2021-09-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.